vimarsana.com

Latest Breaking News On - Hematopoietic stem cell transplantation - Page 5 : vimarsana.com

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients.Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET)MARSEILLE, France (BUSINESS WIRE) #immunotherapy Innate Pharma S.

FDA approves groundbreaking, genetic-based treatments for sickle cell disease

The FDA has approved a pair of powerful new treatments for sickle cell disease.The therapies work by genetically modifying a patient's stem cells.Until now, the

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.